[ACN Newswire] – By David MoskowitzShares of Endo Pharmaceuticals (NASDAQ:ENDP) are trading at a deep discount to other pharmaceutical companies, with the last dip in price coming on the heels of guidance at the company’s … moreView todays social media effects on ENDPView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David MoskowitzEndo Pharmaceuticals (NASDAQ:ENDP) is hosting its analyst day today in NY, and despite guiding for lower 2013 revenues and EPS compared to Wall Street Consensus estimates, we believe … moreView todays social media effects on ENDPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – CHADDS FORD, Pa., Oct. 4, 2012/PRNewswire-FirstCall/ — Highlights long-term growth drivers and investment attributes of the company Endo updates 2012 performance, reaffirms full year 2012 revenues of … moreView todays social media effects on ENDPView the latest stocks trending across Twitter. Click to view dashboard […]
